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LEITER TO THE EDITOR 
T -Cell Vaccination in Patients with Nickel Allergic 
Contact Dermatitis 
To the Editor: 
T -cell vaccination (TCV) is a novel type of specific immunotherapy 
for T - cell-mediated diseases. Auto logous disease relevant T lym-
phocytes are selected and grown irr c1itro, rendered avirulent, and 
reinjected, which may induce an antigen-specific immunosuppres-
sion. The effect of TCV is possibly due to the up-regulation of a 
suppressive anticlonotypic response directed at the disease indu cing 
T cells [1 ]. TCV has been demonstrated to be effective i11 the 
treatment of animal mod els of T-cell-ITlediated diseases u1cluding 
contact sensitivity [2]. ln a previous study we investigated the 
feas ibili ty of TCV in patients with rhe umatoid arthritis (3] . The 
vaccu1es used in that study were pz·epare d fi·om T ceUs of undefin ed 
sp ecificity. Therefore the m odulation of a particular immune 
response could not be monitored. For this reason it was decided to 
study TCV in a T- cell-mediated disease in which the disease 
causu1g antigen is defin ed. Nickel all ergic contact dermatitis is such 
a disease. Nickel-reactive T lymphocytes can be grown from nickel-
induced skin lesions [4] as well as from the peripheral blood [5] o f 
nickel aUergic patients. In the present study, w hich was approved 
by the M edi cal Ethics Committee of our hospital, five patients with 
nickel aiJergy were vaccinated w ith autologous nickel-specifi c 
T - ce iJ lines. T hree patients were vaccinated once and two patients 
nvice. The nickel reactivity u1 the periph eral blood and the skin as 
well as the presence of a humoral and cellular anti-va ccine response 
were analyzed before and after (days 2, 14, and 27) vaccination . 
Autologous peripheral blood monon.uclear cells (PBMC ) w ere 
obtained by lymphopheresis and stimulated with optu11al concen-
tration of NiS04 . At day five 25 U / mJ interleukll1-2 was added. 
After 2 weeks cells were restimulated whh PHA or NiS04 • The last 
restimulation was always with NiS04 • Forty-eight hours after tlus 
restilnulation 100-200 X 106 activated T cells were fixed with 
formaldehyd e (0.3% on ice for 15 min) , washed, suspended in 1 ml 
salu1e and inj ected subcutaneously in the upper arm. ln all patients 
the vaccme contained more than 90'Vu T cells, the majority of which 
were activated based on interl eukll1-2 receptor and HLA class lJ 
expression. The CD4/CD8 ratio varied fi-om 0.3 to 5.4. T he cell 
lines used for vaccin ation showed good proliferative responses 
versus NiS04 and, except for one cell line that also proliferated 
agauut candida, not versus the recall antigens tested (tetanus 
tox oid , candida, purified protein derivative of Mycobacter·ium 
tuberculosis, and varicella) . The T - ceil receptor (TCR) V{3 gene 
usage of the cell lines used for vaccination was analyzed by a 
semiquantitative polymerase chain reaction (PCR) technique and 
compared with that of a PHA-propaga ted T - cell line of the same 
patient. In one patient oligoclonality of the vaccine was observed 
with increased expt·ession of the TCR V{3 2 ru1d Vf315 genes. In the 
other nickel-reactive T-cell lines expression of all TCR Vf3 genes 
tested could be observed, although the expression of several TCR 
Vf3 genes was il1ereased, in particular TCR Vf3 19 and 21 genes. 
TCV w as well tolerated. Apart from the fact that one patient 
complained about pain at the site of u1j ection, no side effects were 
observed. Follow-up of the patients was done up to half a year. 
Patients were checked fo r side effects by history and local exami-
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nation of the site of injection . Nickel reactivity before and after 
vaccination was monitored itr r'itro and itr c1ivo. 
Because of the marked inter-assay variability of the lymphocyte 
stimulation tests with nickel, no clear difFerences after vaccination 
could be observed. Also, the standard reading of the patch tests 
with nickel before and after vaccu1ation did not ch ange with th e 
exception of one patient who went from a + + + to a + + reaction. 
Besides the st;mdard scoring of the patch tests, the cutaneous blood 
flow (CBF) at the site of the patch test was detemuned by laser 
Doppler flo wm etry, before and afte r vaccination (see Fig 1). In two 
patients a marked decrease in the CBF could be observed after 
vaccination and u1 one patient a sligh t decrease. Both patients that 
were revaccinated showed a m arked decrease u1 CBF after revac-
cmation. Laser Dopp ler flowme try has been shown to be an 
accurate and reproducible me thod of eva]uating skill reactions [6] . 
Thus, the discrepancy with the visual scores indicates that the 
changes in cutaneous reactivity against nickel as measured by laser 
Doppler flowmetry are too small to be detected by the visual 
scori11g of the primary skin lesion. Unfortunately, none of the 
patients studied displayed skill reactivity against other allergens. 
Therefore it could not be determined whether the decrease in the 
cutaneous reactivity against tuckel upon vaccu1ation was antigen-
sp ecific. 
Anti-vaccine responses were tested by skin testil1g, lymphocyte 
stllnulation tests and screenil1g for antibodies directed agail1st lympho-
cytes. Skin testil1g yie lded negative results: no induration at the site 
of the injection of the vaccine and only minimal erytJ1ema could be 
observed, botl1 before and after (re-)vaccination. Lymphocyte 
stimulation tests with the irradiated vaccine cells tested in several 
ways also f."liled to show evidence for a vaccme-directed response 
induced by T-ceiJ vaccination. Interestingly, cl1ree patients devel-
oped cytotoxic antibodies against pedpheral blood monon uclear 
cells from a panel of donors . T his response was particularly striking 
in one patient, who also showed a clear rise u1 reactivity against 
autologous PBMC as well as against the T - cell lin e used for 
vaccil1ation. T herefore, the serum sample of tlus patient after 
vaccu1ation was tested in more detail. Polyethyleneglycol precipi-
tation (to discriminate between antibodies and immune complexes) 
showed that cytotoxicity was present both in the supernatru1t 
(antibodies) as well as in the pellet (immune complexes), but most 
strongly in the supernatant. Pre-incubation of the serum with 
dithiothreitol completely abolished cyto toxicity, and the optimal 
temperature for the serum to cause cell lysis was 4°C. From tlus we 
concluded that the cytotoJ<ricity was m all probability due to 
cold-reactive IgM antibodies. 
Cold-reactive antibodies of the IgM class against autologous and 
donor lymphocytes have been described fi·equently m dialysis 
patients and also after viral infections [7]. It was speculated that 
formalinization of the trapped w lute blood cells on dialysis mem-
bra11es may change the antigenicity of these cells , so that on 
subsequent dialysis the patient is sensitized to Ius "altered" autol-
ogous antigens . In analogy fixation of the vaccine w ith tormalde-
hyde nught have been responsible for the induction of such 
antibodi es in the present study. 
T his experience with TCV u1 patients with nickel-allergic con-
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Figure 1. Changes in the cutaneous blood flow at the site of 
application of nickel upon TCV. Patients were patch tested with NiS0 4 
before and after (re-)vaccination and the cutaneous blood flow at the site of 
application was determined by laser Doppler Aowmetry. On the x-axis arc 
depicted the timepoiuts, on whjch the patients were patch tested, on the 
y-axis the values for the cutaneous blood flow. Each symbol refers to a 
different patient. 
tact dermatitis confim1ed that TCV is technically feasible and safe. 
We found i11 JJivo but not i11 JJitro ev idence for a decreased reactivity 
against nickel after vaccination. FinaJiy, we perhaps observed the 
development of a humoral (in one patient) but not of a cellular 
immune response against the vaccine . These results show at least 
som e immunomodulatory effect ofT -cell vaccination, although the 
antigen specificity of this effect remai11s to be shown. However, 
tmtior questions regarding the immunogenicity ofT -cell vaccines 
and monitoring its effect remain unanswered. 
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